Abstract
Antibodies to various core glycolipid antigens have been shown to correlate with survival from Gram-negative sepsis. Recent preclinical data also support efficacy of the anti-core glycolipid antibodies in the treatment of sepsis. Failure of some of the previous clinical trials with anti-core glycolipid antibody was probably due to inadequate levels of antibody in those preparations. Future clinical trials must ensure that sufficient amounts of anti-core glycolipid antibodies are present in the circulation of patients with sepsis.
MeSH terms
-
Animals
-
Antibodies, Bacterial / therapeutic use*
-
Antibodies, Monoclonal / therapeutic use
-
Bacterial Vaccines / immunology*
-
Bacterial Vaccines / therapeutic use
-
Endotoxins / chemistry
-
Endotoxins / immunology
-
Glycolipids / immunology
-
Gram-Negative Bacterial Infections / prevention & control
-
Gram-Negative Bacterial Infections / therapy*
-
Humans
-
O Antigens / chemistry
-
O Antigens / immunology
-
Sepsis / prevention & control
-
Sepsis / therapy*
-
Vaccination
Substances
-
Antibodies, Bacterial
-
Antibodies, Monoclonal
-
Bacterial Vaccines
-
Endotoxins
-
Glycolipids
-
O Antigens